Krilogy Financial LLC lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 92.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 20,872 shares of the company’s stock after buying an additional 10,050 shares during the quarter. Krilogy Financial LLC’s holdings in CRISPR Therapeutics were worth $1,127,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Global Trust Asset Management LLC raised its holdings in shares of CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after buying an additional 300 shares during the period. GPS Wealth Strategies Group LLC lifted its stake in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the last quarter. Riggs Asset Managment Co. Inc. grew its holdings in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $41,000. Finally, NBC Securities Inc. raised its holdings in shares of CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.
Insider Activity
In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Report on CRISPR Therapeutics
CRISPR Therapeutics Stock Performance
CRISPR Therapeutics stock traded up $0.92 during mid-day trading on Wednesday, reaching $49.99. 1,108,313 shares of the company were exchanged, compared to its average volume of 1,573,917. The firm’s 50-day simple moving average is $55.02 and its two-hundred day simple moving average is $61.96. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm has a market cap of $4.25 billion, a PE ratio of -18.17 and a beta of 1.70.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.98) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.52 EPS for the current year.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- About the Markup Calculator
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Investing In Preferred Stock vs. Common Stock
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.